SeneXta Therapeutics was initially founded to acquire intellectual properties related to the treatment of Alzheimer's disease (AD) and stroke (SNX-001).
SeneXta develops its pipeline using a virtual model made of international scientific experts, clinicians, CNS opinion leaders and well-known service providers (CROs and CMOs).
The company has established solid collaborations with US and European Universities. These alliances allow SeneXta to utilize R&D capacity of large institutions for the development of new compounds. 
SeneXta is focused on products that are in advanced clinical stage of development and have higher probability of success.